Cargando…

Recurrence or reactivation of SARS-CoV-2 infection after immunosuppressive therapy in patients with ANCA-associated vasculitis and COVID-19

Abstract. Acute tubular injury is the lesion most frequently described in this disease. However, four cases of ANCA-associated vasculitis (AAV) with COVID-19 with pauci-immune glomerulonephritis have recently been described. We report the case of an African woman, aged 70, in whom we diagnosed an AA...

Descripción completa

Detalles Bibliográficos
Autores principales: Mbengue, Mansour, Bigirimana, Bede, Irankunda, Lolly Romeo, Dial, Mohamed Cherif, Niang, Abdou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dustri-Verlag Dr. Karl Feistle 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750963/
https://www.ncbi.nlm.nih.gov/pubmed/35028280
http://dx.doi.org/10.5414/CNCS110567
_version_ 1784631580238544896
author Mbengue, Mansour
Bigirimana, Bede
Irankunda, Lolly Romeo
Dial, Mohamed Cherif
Niang, Abdou
author_facet Mbengue, Mansour
Bigirimana, Bede
Irankunda, Lolly Romeo
Dial, Mohamed Cherif
Niang, Abdou
author_sort Mbengue, Mansour
collection PubMed
description Abstract. Acute tubular injury is the lesion most frequently described in this disease. However, four cases of ANCA-associated vasculitis (AAV) with COVID-19 with pauci-immune glomerulonephritis have recently been described. We report the case of an African woman, aged 70, in whom we diagnosed an AAV with pauci-immune glomerulonephritis in the context of COVID-19. She was treated with hydroxychloroquine and azithromycin for COVID-19. Corticosteroids and cyclophosphamide have been used for the treatment of vasculitis. The evolution was marked by the reappearance of COVID-19 one month after the beginning of an immunosuppressive therapy. The patient died a week later from respiratory failure. The occurrence of AAV during COVID-19 may not be due an unfortunate association but triggered by infection with SARS-CoV-2. The use of immunosuppressive therapy should be discussed due to the potential risk of reactivation or recurrence of the viral infection.
format Online
Article
Text
id pubmed-8750963
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dustri-Verlag Dr. Karl Feistle
record_format MEDLINE/PubMed
spelling pubmed-87509632022-01-12 Recurrence or reactivation of SARS-CoV-2 infection after immunosuppressive therapy in patients with ANCA-associated vasculitis and COVID-19 Mbengue, Mansour Bigirimana, Bede Irankunda, Lolly Romeo Dial, Mohamed Cherif Niang, Abdou Clin Nephrol Case Stud Case Report Abstract. Acute tubular injury is the lesion most frequently described in this disease. However, four cases of ANCA-associated vasculitis (AAV) with COVID-19 with pauci-immune glomerulonephritis have recently been described. We report the case of an African woman, aged 70, in whom we diagnosed an AAV with pauci-immune glomerulonephritis in the context of COVID-19. She was treated with hydroxychloroquine and azithromycin for COVID-19. Corticosteroids and cyclophosphamide have been used for the treatment of vasculitis. The evolution was marked by the reappearance of COVID-19 one month after the beginning of an immunosuppressive therapy. The patient died a week later from respiratory failure. The occurrence of AAV during COVID-19 may not be due an unfortunate association but triggered by infection with SARS-CoV-2. The use of immunosuppressive therapy should be discussed due to the potential risk of reactivation or recurrence of the viral infection. Dustri-Verlag Dr. Karl Feistle 2022-01-05 /pmc/articles/PMC8750963/ /pubmed/35028280 http://dx.doi.org/10.5414/CNCS110567 Text en © Dustri-Verlag Dr. K. Feistle https://creativecommons.org/licenses/by/2.5/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Mbengue, Mansour
Bigirimana, Bede
Irankunda, Lolly Romeo
Dial, Mohamed Cherif
Niang, Abdou
Recurrence or reactivation of SARS-CoV-2 infection after immunosuppressive therapy in patients with ANCA-associated vasculitis and COVID-19
title Recurrence or reactivation of SARS-CoV-2 infection after immunosuppressive therapy in patients with ANCA-associated vasculitis and COVID-19
title_full Recurrence or reactivation of SARS-CoV-2 infection after immunosuppressive therapy in patients with ANCA-associated vasculitis and COVID-19
title_fullStr Recurrence or reactivation of SARS-CoV-2 infection after immunosuppressive therapy in patients with ANCA-associated vasculitis and COVID-19
title_full_unstemmed Recurrence or reactivation of SARS-CoV-2 infection after immunosuppressive therapy in patients with ANCA-associated vasculitis and COVID-19
title_short Recurrence or reactivation of SARS-CoV-2 infection after immunosuppressive therapy in patients with ANCA-associated vasculitis and COVID-19
title_sort recurrence or reactivation of sars-cov-2 infection after immunosuppressive therapy in patients with anca-associated vasculitis and covid-19
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750963/
https://www.ncbi.nlm.nih.gov/pubmed/35028280
http://dx.doi.org/10.5414/CNCS110567
work_keys_str_mv AT mbenguemansour recurrenceorreactivationofsarscov2infectionafterimmunosuppressivetherapyinpatientswithancaassociatedvasculitisandcovid19
AT bigirimanabede recurrenceorreactivationofsarscov2infectionafterimmunosuppressivetherapyinpatientswithancaassociatedvasculitisandcovid19
AT irankundalollyromeo recurrenceorreactivationofsarscov2infectionafterimmunosuppressivetherapyinpatientswithancaassociatedvasculitisandcovid19
AT dialmohamedcherif recurrenceorreactivationofsarscov2infectionafterimmunosuppressivetherapyinpatientswithancaassociatedvasculitisandcovid19
AT niangabdou recurrenceorreactivationofsarscov2infectionafterimmunosuppressivetherapyinpatientswithancaassociatedvasculitisandcovid19